H.C. Wainwright analyst Ananda Ghosh believes Inventiva’s (IVA) lanifibranor “stands out” as the only pan PPAR agonist in Phase 3 with dual histologic benefit already demonstrated in Phase 2b. This positions Inventiva as the next acquisition target following the buyout of 89bio (ETNB) by Roche (RHHBY), the analyst tells investors in a research note. H.C. Wainwright believes lanifibranor is “emerging as a prime acquisition candidate” for a big pharma company seeking a differentiated, fibrosis directed, cardiometabolic oral backbone to complement GLP-1s and FGF21s.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IVA:
- Buy Rating for Inventiva: Lanifibranor’s Promising Role in Metabolic Disease Treatment
- 3 Best Stocks to Buy Now, 9/4/2025, According to Top Analysts
- Inventiva assumed with a Buy at H.C. Wainwright
- Inventiva price target raised to $13 from $9 at Guggenheim
- 3 Best Stocks to Buy Now, 8/28/2025, According to Top Analysts